ONYX PHARMA - Testing Time Ahead in the Hematological Cancer Space
Despite better uptake of Nexavar (L, RCC, HCC) in Asia-Pacific region, increasing expenses have wiped out the profits. All Hopes tied to the Approval of Carfilzomib (PhIIb, next-generation proteasome inhibitor, Relapsed and Refractory Multiple Myeloma - R/R MM). There are two registration PhIII trials underway and interim data from these studies are expected to be out only in … For more detail, please read our report released on 2nd September, 2011 on ONXX titled “Testing Time Ahead in the Hematological Cancer Space”.
COMPANIES MENTIONED
Onyx Pharma
Onyx Pharma
More Publications
INCYTE: Testing Time Ahead For JAKAFI
US$ 140.00
February 2012
3 pages
Vertex – “Testing Time Ahead for INCIVEK - After 2013!”
US$ 140.00
November 2011
10 pages
Onyx Pharma - Banking on Carfilzomib’s Approval or Acquisition!
US$ 90.00
March 2012
4 pages
Onyx Pharma – Kyprolis to Accelerate Growth
US$ 140.00
June 2012
4 pages
Onyx Pharma, Market Perform - M&A Rumors Fuel Investors Interest and Stock Movement
US$ 90.00
November 2011
6 pages
